 Transplanted hypoimmune HIP-modified allogeneic CD19-targeted CAR T cells control CD19 tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems Allogeneic HIP CAR T cells can be produced with novel gene editing platform CRISPRCas12b at large scale and high gene-editing efficiency HIP-modified allogeneic BCMA-targeted CAR T cells demonstrate in ... The post Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in... 